Elevance Health Dips 0.23% as $530M Volume Ranks 182nd in Market Activity Despite Strong Buy Ratings and 14.99% Earnings Growth Outlook

On September 3, 2025, Elevance Health (ELV) declined 0.23% with a trading volume of $0.53 billion, ranking 182nd in market activity. Analysts remain cautiously optimistic, with 12 out of 18 ratings favoring a "Buy" and a consensus "Moderate Buy" score of 2.67. Earnings are projected to grow by 14.99% to $39.05 per share, supported by a P/E ratio of 13.58, significantly below the market and healthcare sector averages. The stock’s PEG ratio of 1.13 and P/B ratio of 1.63 suggest mixed valuation signals, balancing growth potential with asset-based affordability.

Dividend strength remains a key highlight, with a 2.21% yield and a sustainable payout ratio of 29.11%. Institutional ownership at 89.24% underscores confidence, while insider buying of $2.81 million over three months contrasts with a 4.41% rise in short interest, signaling mixed investor sentiment. News sentiment analysis revealed a score of 1.52, outperforming the healthcare sector average, though 27 articles tracked in the past week indicate moderate market engagement.

Backtest results for ELV show an average price target of $413.81, implying a 29.72% potential upside from its current level. Analysts have issued 18 ratings in the last year, with 12 "Buy," 6 "Hold," and no "Sell" recommendations. Recent downgrades, including a shift from "Outperform" to "Market Perform" by Leerink Partners, highlight evolving risk assessments. The stock’s short interest ratio of 1.2 days to cover remains within typical ranges, reflecting manageable bearish pressure.